Harnett P R, Raghavan D, Caterson I, Pearson B, Watt H, Teriana N, Coates A, Coorey G
Br J Urol. 1987 Apr;59(4):323-7. doi: 10.1111/j.1464-410x.1987.tb04641.x.
We have treated 34 patients with advanced prostate cancer, resistant to orchiectomy or oestrogen therapy, with aminoglutethimide. Seven patients (21%) showed improvement in pain and performance status for prolonged periods. By NPCP criteria six patients had stable disease and one had partial tumour response. Six of these patients remained on oestrogen therapy. Suppressed gonadotrophin levels (FSH and LH), despite orchiectomy, correlated strongly with benefit from aminoglutethimide. No relationships between response to treatment and changes in serum testosterone, dehydroepiandrosterone, oestradiol or prolactin were found. Six patients had side effects requiring cessation of therapy. A further 27 patients developed less severe toxicity. Despite its toxicity, these results show that aminoglutethimide has a role in the management of advanced prostatic cancer resistant to primary hormonal manipulation.
我们用氨鲁米特治疗了34例对睾丸切除术或雌激素治疗耐药的晚期前列腺癌患者。7例患者（21%）在较长时间内疼痛和身体状况有所改善。根据NPCP标准，6例患者病情稳定，1例患者肿瘤部分缓解。这些患者中有6例仍在接受雌激素治疗。尽管进行了睾丸切除术，但促性腺激素水平（FSH和LH）受到抑制与氨鲁米特治疗获益密切相关。未发现治疗反应与血清睾酮、脱氢表雄酮、雌二醇或催乳素变化之间存在关联。6例患者出现需要停药的副作用。另有27例患者出现较轻的毒性反应。尽管有其毒性，但这些结果表明氨鲁米特在治疗对初始激素治疗耐药的晚期前列腺癌中具有一定作用。
